Xenon Pharmaceuticals Inc.
XENE evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $5.63B
- Lead Asset:
- xen1101 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for XENE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XENE
Xenon Pharmaceuticals Inc. (XENE) is a neuroscience-focused biopharmaceutical company advancing clinical-stage programs in epilepsy, major depressive disorder, and bipolar disorder, with its lead asset azetukalner in Phase 3 trials.
Key risk: Pre-revenue stage
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 14 clinical trials for Xenon Pharmaceuticals Inc..
Similar companies
Xenon Pharmaceuticals Inc. (XENE) is a neuroscience-focused biopharmaceutical company advancing clinical-stage programs in epilepsy, major depressive disorder, and bipolar disorder, with its lead asset azetukalner in Phase 3 trials.
- Lead asset azetukalner is in Phase 3 trials for focal onset seizures (X-TOLE2, X-TOLE3), primary generalized tonic-clonic seizures (X-ACKT), major depressive disorder (X-NOVA2, X-NOVA3), and bipolar disorder (X-CEED) [sec_mda · as of 2026-08-06].
- Positive topline Phase 3 X-TOLE2 data in focal onset seizures was announced on March 9, 2026, supporting a planned FDA NDA submission in Q3 2026 [news · published 2026-05-11].
- Cash & equivalents of $119.5M as of 2026-06-30, with shareholders' equity of $1,242.4M and net income of -$110.7M for the quarter [latest reported financials].
- Accumulated deficit of $1,458.4 million as of 2026-08-06, primarily from R&D and general/administrative costs [sec_mda · as of 2026-08-06].
- Enrollment is ongoing in multiple Phase 3 studies, with topline data from X-NOVA2 (MDD) expected in H1 2027 [sec_mda · as of 2026-08-06].
What works
- Positive Phase 3 X-TOLE2 topline data in focal onset seizures announced March 9, 2026, supporting a planned FDA NDA submission in Q3 2026 [news · published 2026-05-11].
- Multiple Phase 3 programs are advancing across epilepsy, MDD, and BPD, indicating a broad pipeline [sec_mda · as of 2026-08-06].
- Company expects existing cash and marketable securities to fund operating expenses for at least the next 12 months as of 2026-08-06 [sec_mda · as of 2026-08-06].
- Mechanistic data suggests azetukalner may offer additive benefits in combination with commonly used anti-seizure medications [news · published 2026-08-28].
What to weigh
- Net loss of $110.7M for the quarter ended 2026-06-30, with accumulated deficit of $1,458.4M as of 2026-08-06 [latest reported financials; sec_mda · as of 2026-08-06].
- No revenue reported as of 2026-06-30, indicating the company is pre-commercial [latest reported financials].
- Operating expenses are expected to increase substantially as the company prepares for potential commercial launch and further development [sec_mda · as of 2026-08-06].
- Cash & equivalents of $119.5M as of 2026-06-30, a significant drop from the $1.34B in cash and marketable securities reported at end of Q1 2026 [latest reported financials; news · published 2026-05-11].
From the filings
Quoted directly from source documents.
Positive Phase 3 X-TOLE2 topline data announced March 9, 2026
“positive topline data announced on March 9, 2026”
SEC filings · April 22, 2026
Planned FDA NDA submission in Q3 2026
“supporting a planned FDA New Drug Application submission in the third quarter of 2026”
News · May 11, 2026
Accumulated deficit of $1,458.4 million as of 2026-08-06
“we had an accumulated deficit of $1,458.4 million”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- Pre-revenue stage — No revenue reported as of 2026-06-30; company depends on financing to fund operations [latest reported financials].
- High accumulated deficit — Accumulated deficit of $1,458.4M as of 2026-08-06, with net losses continuing [sec_mda · as of 2026-08-06].
- Cash burn rate — Cash & equivalents dropped from ~$1.34B (Q1 2026) to $119.5M (Q2 2026), though equity remains high [news · published 2026-05-11; latest reported financials].
- Clinical trial execution — Multiple Phase 3 trials ongoing; delays or negative data could impact timelines and funding [sec_mda · as of 2026-08-06].
What to watch
- FDA NDA submission for azetukalner in focal onset seizures, planned for Q3 2026 [news · published 2026-05-11].
- Topline data from Phase 3 X-NOVA2 (MDD) expected in H1 2027 [sec_mda · as of 2026-08-06].
- Completion of enrollment in X-TOLE3 and X-ACKT epilepsy studies, with X-ACKT enrollment outside Japan expected to complete in 2026 [sec_mda · as of 2026-08-06].
- Cash runway and potential need for additional financing given pre-revenue status and high operating expenses [sec_mda · as of 2026-08-06].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run Xenon Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Xenon Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.04 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
0 buys · 3 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 5.0%
- Days to cover
- 4.1
- Shares short
- 4,854,352
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XENE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. (XENE) is a neuroscience-focused biopharmaceutical company advancing clinical-stage programs in epilepsy, major depressive disorder, and bipolar disorder, with its lead asset azetukalner in Phase 3 trials.
What is Xenon Pharmaceuticals Inc.'s lead drug candidate?
Xenon Pharmaceuticals Inc.'s most advanced tracked candidate is xen1101 (Phase 2) for Focal Epilepsy; Major Depressive Disorder; Focal Onset Seizures.
Who is the CEO of Xenon Pharmaceuticals Inc.?
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. is the chief executive officer of Xenon Pharmaceuticals Inc. (XENE).
Where is Xenon Pharmaceuticals Inc. headquartered?
Xenon Pharmaceuticals Inc. (XENE) is headquartered in Burnaby, BC, Canada.
What therapeutic areas does Xenon Pharmaceuticals Inc. focus on?
Xenon Pharmaceuticals Inc. develops therapies across Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.